AI tool predicts Parkinson's progression and medication side effects using a smartwatch
Tests AI models using smartwatch data and health records in adults with Parkinson's disease.
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- Toulouse, FranceSee the siteAlso in 3 other countries, 3 sites
- Trial code
- Registry title
- AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 6 Oct 2025
- Expected to end
- 1 Apr 2027
- Type of study
- Observational
- Treatments tested
- Smartwatch and mobile application
- Record updated
- 24 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 80 with Parkinson's disease for 5 to 10 years, in stages 2 and 3, who use a compatible smartphone.
- Age
- 40 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease diagnosed by MDS criteria, disease duration 5 to 10 years, Hoehn and Yahr stages 2 and 3 in the ON condition.
- Earlier treatment
- People on second-line device-aided treatments cannot join. People taking more than 4 daily doses of L-DOPA, or a daily levodopa equivalent dose above 1500 mg, cannot join.
Main reasons for not taking part
- Atypical Parkinsonian syndrome
- Second-line device-aided treatments
- More than 4 daily doses of L-DOPA, or daily levodopa equivalent dose above 1500 mg
- Ongoing hallucinations needing short-term treatment adjustment
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015)
- Disease duration ranging from 5 to 10 years
- Age 40-80
- Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition
- The participant is using a compatible smartphone
- Written informed consent
Who cannot take part
- Atypical Parkinsonian Syndrome
- Second-line device-aided treatments
- Patients with >4 daily doses of L-DOPA
- Daily levodopa equivalent dose > 1500 mg
- Ongoing hallucinations requiring short-term treatment adjustment
- Inability to provide informed consent or participate in the study
- Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator
- Lacking motivation to participate in study procedures - as judged by investigator
- Under adult autonomy protection system, legal guardianship or incapacitation
- Pregnant and breast-feeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Where in France
Also in 3 other countries, 3 sites
- University Hospital of ToulouseToulouse, FranceContact: Margherita FABBRI, MDNo longer taking part
About the trial
What the trial wants to find out
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.
The group in the trial
- Parkinson's disease patients
Parkinson's disease patients to be monitored via a smartwatch and a mobile application
Treatment: Smartwatch and mobile application
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
- Plain-language title
- AI tool predicts Parkinson's progression and medication side effects using a smartwatchGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07189468, who can take part
- Record updated
- 24 September 2025